Visual and anatomical gains made with aflibercept monotherapy for polypoidal choroidal vasculopathy were maintained long term, according to a study looking at the second-year data of the PLANET trial.
“The trial confirms the 2-year effectiveness of using anti-VEGF monotherapy with aflibercept (Eylea, Regeneron) in treating a common subtype of AMD, which is polypoidal choroidal vasculopathy (PCV), based on the PLANET trial protocol,” Tien Wong, MD, PhD, professor and medical director at the Singapore National Eye Center and chairman of the Singapore Eye Research Institute, told
Uncategorized